XOMA vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Captures Institutional Edge (3โ1 Pillars ยท 2โ8 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while XOMA counters with relative strength in Valuation. Fundamentally, XOMA trades at 21.5x Forward P/E with -3.9% operating margin (-22.6% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XOMA | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $781.8M | $503.1M | Larger Scale | XOMA |
| Trailing P/E Ratio Valuation | 28.2x | N/M | Lower Multiple | XOMA |
| Forward P/E Ratio Valuation | 21.5x | N/M | Lower Multiple | XOMA |
| Revenue Growth (YoY) Growth | -22.6% | +0.0% | Higher Growth | DMAC |
| Operating Margin (TTM) Profitability | -3.9% | 0.0% | Higher Margin | DMAC |
| Net Profit Margin Profitability | 69.6% | 0.0% | Higher Margin | XOMA |
| Return on Equity (ROE) Capital Efficiency | 34.2% | -114.6% | Higher ROE | XOMA |
| 52-Week Range Position Momentum | 78% ($22โ$45) | 55% ($5โ$11) | Stronger Trend | XOMA |
| Beta / 30D Volatility Risk Regime | 0.68ฮฒ ยท 37% Vol | 1.74ฮฒ ยท 98% Vol | Lower Realized Risk | XOMA |
| Unified Institutional Score Composite Signal | 55.8 / 100 (HOLD) | 46.3 / 100 (HOLD) | Higher Composite | XOMA |